The authorization could ease cost pressures on group benefit plan sponsors covering GLP-1 drugs
Health Canada has authorized the first generic semaglutide injection indicated for weight loss, according to a release by the federal regulator Monday evening.
The move marks a regulatory milestone that could reshape the cost calculus for Canadian group benefit plan sponsors grappling with surging GLP-1 drug claims.
The product, known as Svemia, was filed by Canadian-based Apotex and is a generic version of the brand-name drug Wegovy. It is indicated for the once-weekly treatment of patients aged 12 and over as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management.
Svemia is the third generic semaglutide product Health Canada has approved. The regulator authorized a generic semaglutide injection from Apotex for the once-weekly treatment of adult patients with type 2 diabetes on May 1 and became the first G7 country to approve any generic version of the drug on April 28. Six additional generic semaglutide submissions from different companies are currently under review, with further regulatory decisions expected in the coming weeks and months.
"Health Canada's review ensures that differences between these products do not affect the safety, efficacy, or quality of the drug. The availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for patients and the healthcare system," the department said in a statement.
The arrival of generic alternatives comes at a critical time for employer-sponsored drug plans. GLP-1 receptor agonists have driven significant cost increases across Canadian group benefits portfolios, with some insurers flagging the drug class as a top contributor to rising claims. Generic medications in Canada are typically 45 to 90 per cent cheaper than their brand-name equivalents, according to Health Canada, suggesting meaningful savings could flow through to plan sponsors and their members as the generic pipeline expands.
Health Canada noted that while generic semaglutide products are complex synthetic versions that are pharmaceutically equivalent to the brand-name biologic, its review process ensures that differences between the products do not affect safety, efficacy or quality.
The regulator said it will continue to monitor the safety and effectiveness of all generic semaglutide products authorized in Canada and will take action if unexpected concerns arise.
